EU to authorise drug remdesivir for severe Covid-19 cases

A bottle of the drug remdesivir being used in clinical trials. The EU is to authorise drug the remdesivir for severe Covid-19 cases.
The EMA made its decision after the drug proved effective in scientific studies including a major US clinical trial.

The European Medicines Agency (EMA) has recommended that the drug remdesivir be “conditionally” sold for the treatment of severe Covid-19 in the EU, making it the first Covid-19 drug set to be authorised in Europe.

The “conditional marketing authorisation” was released this week (Thursday June 25). This means that the drug can be sold in the EU for use against Covid-19 for a year, pending a “fast track” approval from the European Commission, which is expected within a week.

This approval allows “early access to medicines that fulfil an unmet medical need, including in emergency situations in response to public health threats such as the current pandemic”, the EMA wrote.

“This type of approval allows the Agency to recommend ...

To read the remaining 85% of this article, you need to either

Subscribe now to The Connexion and benefit from access to our archived articles since 2006

Print + Digital 3 month subscription

Pay every three months. Our most flexible subscription.

Automatic renewal, cancel anytime

€14.25 to France - €18 to EU/UK - €19.50 to rest of the world per quarter including postage

Print + Digital 1 year subscription

1 year of great reading in print and online

Automatic renewal, cancel anytime

€55 to France - €70 to EU/UK - €76 to rest of the world per year including postage

Digital 1 year subscription (Our best value offer)

1 year of great reading online *no paper*

Automatic renewal, cancel anytime

Digital 3 month subscription

3 months of great reading online *no paper*

Automatic renewal, cancel anytime

More articles from French news
More articles from Connexion France
Other articles that may interest you